By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Biotech firm HemoShear today announced a $4.3 million Phase II Small Business Innovation Research grant to profile the effects of 50 known drugs on the human blood vessel system using the company's proprietary human vascular surrogate system.

The grant, the third received by the Charlottesville, Va.-based company in the past two years, is from the National Heart, Lung, and Blood Institute.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.